CSC
MDGL icon

Caldwell Sutter Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Caldwell Sutter Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.4K Buy
+118
New +$60.4K 0.02% 372

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Caldwell Sutter Capital's MDGL Position: Q2 2026 in Review

Caldwell Sutter Capital opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 118 shares worth $63.4K. The stake represents 0.02% of the portfolio and ranks #372 among its holdings.

413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Caldwell Sutter Capital held 118 shares of Madrigal Pharmaceuticals worth $63.4K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Caldwell Sutter Capital position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.02% of Caldwell Sutter Capital's portfolio in Q2 2026, its #372 holding.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.